Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Editas Medicine

Elevation Oncology

Fate Therapeutics

Century Therapeutics

Y-Mabs Therapeutics Inc

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

J&J's future prospects look brighter than its year-to-date stock performance might imply.

3 Reasons Why Johnson & Johnson Stock Could Rebound After a Bad Start in 2023

Investors were on the fence about the company's performance in the final months of last year.

Why Johnson & Johnson Stock Was Stagnant Today

J&J reported its Q4 results with EPS beating expectations. The company is proving capable of maintaining organic sales growth while supporting margins through cost savings initiatives.

Johnson & Johnson Q4 Earnings Highlight Bullish Path In 2023

Johnson & Johnson's consumer business was the only division to deliver growth in the fourth quarter.

J&J Gets Ready to Break up With Tylenol

Johnson & Johnson (NYSE:JNJ)'s rosy 2023 earnings forecast failed to take the sting off of moderated sales growth and inflationary pressures during the fourth quarter of 2022. For the three-month period to end December 2022, the consumer products and pharmaceutical giant beat on adjusted profit expectations at $2.35 a share, compared to average analyst estimates of $2.23.

Johnson & Johnson's 4Q earnings beat and rosy 2023 outlook fails to distract from slowing sales growth and inflationary pressures

Johnson & Johnson (NYSE:JNJ ) Q4 2022 Results Conference Call January 24, 2023 8:30 AM ET Company Participants Jessica Moore - VP, IR Joaquin Duato - Chairman and CEO Joe Wolk - EVP and CFO Conference Call Participants Terence Flynn - Morgan Stanley David Risinger - SVB Securities Larry Biegelsen - Wells Fargo Chris Schott - JP Morgan Matt Miksic - Barclays Chris Shibutani - Goldman Sachs Louise Chen - Cantor Fitzgerald Operator Good morning and welcome to Johnson & Johnson's Fourth Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Q4 2022 Earnings Call Transcript

As cases of COVID, flu and respiratory syncytial virus surged in the fall as part of a “tripledemic” in the U.S., demand for cold medications translated to a good quarter for Johnson & Johnson's JNJ consumer health business.

‘Tripledemic' demand for Motrin and Tylenol fueled year-end sales in J&J's consumer business

The company continues to see pressure on sales from staffing shortages at hospitals, which have limited growth in procedures using J&J products, while inflation has boosted expenses.

Johnson & Johnson fourth-quarter earnings down 25%

J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.

J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat

General Electric

Travelers

Whether pre-market futures are reacting to results or just doing some profit-taking off recent highs is hard to tell -- the Dow is -150 points at this hour, the S&P 500 is -20 and the Nasdaq -85 points currently.

Q4 Earnings Season Heats Up: JNJ, MMM, GE & More

Johnson & Johnson (NYSE: JNJ), on Tuesday, issued encouraging guidance for the full year. Shares are still trading slightly down this morning.

J&J's upbeat guidance brings good news for big pharma

AbbVie

ABM Industries

Abbott Labs

American States Water

Becton, Dickinson and Co.

Black Hills

Commerce Bancshares

Cincinnati Financial

Colgate-Palmolive

California Water Service Group

Dover

Emerson Electric

Federal Realty Investment Trust

H.B. Fuller

Genuine Parts

W.W. Grainger

Hormel Foods

Illinois Tool Works

Kimberly-Clark

Coca-Cola

Lancaster Colony

Leggett & Platt

Lowe's

Dividend Kings have an astounding track record of 50 or more years of higher dividend payouts. I rank the Dividend Kings using Quality Snapshots, a simple yet elegant system for assessing the quality of dividend growth stocks.

The Dividend Kings Ranked By Quality Score

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.86% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Johnson & Johnson (JNJ) Q4 Earnings Top Estimates

Johnson & Johnson reported lighter-than-expected fourth-quarter sales and came in with mixed 2023 guidance, leading JNJ stock to dip. The post Johnson & Johnson Beats Profit Views, But Light Sales, Outlook Chip At Shares appeared first on Investor's Business Daily.

Johnson & Johnson Beats Profit Views, But Light Sales, Outlook Chip At Shares

The healthcare-products company reported declining sales in the fourth quarter as demand dropped for its Covid-19 vaccine.

Johnson & Johnson Fourth-Quarter Earnings Down 25%

Home Depot

Microsoft

All 3 of these dividend stocks pay safe, reliable, and growing dividends

3 Must-Own Dividend Stocks

Adjusted earnings of $2.35 a share in the fourth quarter beat analysts' estimates.

Johnson & Johnson Guides Above Expectations for 2023

Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates as it bets on stronger demand for its pharmaceuticals products and a recovery in its medical devices business.

J&J forecasts strong 2023 profit on strength in pharma unit

NEW BRUNSWICK, N.J.--( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

General Motors

Medtronic

For years, these businesses have impressed investors with their ability to raise quarterly dividend payouts.

News for Johnson & Johnson Stock (JNJ)